cDC1 cells are the main DC subtype responsible for TAA cross-presentation and antitumor CD8+ T-cell activation.29 To test whether TRIMELVax was able to provide MAAs to cDC1 in vivo, we performed an ex vivo antigen cross-presentation assay using sorted cDC1, cDC2 and pDCs from TRIMELVax-vaccinated and control B16-FLT3L tumor-bearing animals (figure 2E and online supplementary figure 5). The gene discussed is MPPE1; the disease is neoplasm.